$LSTA Income Statement | Understand Stock

$LSTA

$1.06 +$0.06 (6.44%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2025	FY2023 12 months to Dec 31, 2024	FY2022 12 months to Dec 31, 2023	FY2021 12 months to Dec 31, 2022	FY2020 12 months to Dec 31, 2021
Revenue
Operating Expenses:
Research and development
In-process research and development
General and administrative
Operating expenses
Operating loss
Other income (expense):
Investment income, net
Other expense, net
Total other income
Net loss before benefit from income taxes and noncontrolling interests
Net loss
Less - net income (loss) attributable to noncontrolling interests
Net loss attributable to Lisata Therapeutics, Inc. common stockholders
Basic and diluted loss per share:
Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share)
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share)
Weighted average common shares outstanding:
Basic (in shares)
Diluted (in shares)

Comments